Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126769 | 0.88 | KDM4E (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21566545 | 0.85 | MEN1 (0.36) | KDM4ECYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL24064577 | 0.84 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL12438076 | 0.80 | KDM4E (0.36) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL13430817 | 0.80 | HDAC3 (0.36) | — | |
| SCHEMBL12608885 | 0.76 | ADRB2 (0.36) | — | |
| SCHEMBL454478 | 0.75 | ALDH1A1 (0.35) | KDM4ECYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL19728773 | 0.73 | HDAC3 (0.32) | — | |
| SCHEMBL25952675 | 0.72 | TSHR (0.40) | TDP1 | |
| SCHEMBL10092557 | 0.72 | KDM4E (0.42) | KDM4ECYP1A2CYP2D6CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | KDM4E 1873/4885CYP1A2 4130/4885CYP2D6 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.